Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2023-01-25 Investor Presentation
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release from Pherecydes Pharma dated January 25, 2023. The primary content announces the company management's participation schedule for upcoming scientific conferences and investor events throughout 2023. It also mentions the date for the upcoming Annual Results 2022 publication. This type of announcement, detailing future corporate events, investor outreach, and scheduling, is best classified as a general corporate announcement or investor relations update. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it is primarily focused on investor engagement and scheduling, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* participation. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for scheduling updates that don't fit specific categories like ER or CT. However, since it is explicitly about investor events and future financial reporting dates, it is a strong candidate for a general Investor Relations communication. Given the available codes, RNS is the most appropriate catch-all for this type of forward-looking schedule announcement that isn't a formal report or specific transaction notice.
2023-01-25 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 96% confidence The document is titled "Bilan semestriel du contrat de liquidité de Pherecydes Pharma conclu avec la société Portzamparc" (Semi-annual balance sheet of the liquidity contract of Pherecydes Pharma concluded with Portzamparc). It details the holdings and transactions (purchases and sales) related to a liquidity contract over the second half of 2022 (ending December 31, 2022). This type of regular reporting on market making or liquidity provision activities, especially when presented as a periodic summary (semi-annual balance sheet), is a specific type of corporate disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It relates to the management of the company's shares/capital structure via a third party, which aligns closely with activities related to share transactions or capital management, but the specific context is a mandated report on a liquidity contract. Given the options, this document reports on the status of a specific financial arrangement concerning share trading, which is most closely related to share transactions or capital structure updates. However, since it is a formal, periodic report detailing the activity of a liquidity contract, it is a specialized regulatory disclosure. It is not a standard financial statement (IR/10-K) or a management discussion (MDA). It is a report on share activity, but not a Director's Dealing (DIRS) or a general Share Issue (SHA). In the context of French market practices, these liquidity contract reports are often filed as regulatory updates. Since it is a detailed report on share transactions managed under a specific agreement, it touches upon 'Transaction in Own Shares' (POS) or general regulatory filings. Given the detailed nature of the report on transactions (buy/sell volumes and values) under a liquidity agreement, it is best classified as a report detailing share transactions, fitting best under 'Transaction in Own Shares' (POS) or as a general 'Regulatory Filing' (RNS) if POS is too narrow. Since the document is a detailed report itself (16k+ characters) and not an announcement of a report, we avoid RPA/RNS based on the 'Menu vs Meal' rule if a better fit exists. The core activity described is the execution of share transactions (buying and selling) under a contract. Therefore, POS (Transaction in Own Shares) is the most specific fit for reporting on managed share transactions, even if initiated by a market maker.
2023-01-04 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is titled "Pherecydes Pharma Announces its Financial Agenda for 2023" and explicitly lists future dates for key corporate events such as the release of full-year results, the shareholders' general meeting, and half-year results. This type of announcement, which schedules future reporting events rather than containing the reports themselves, is best classified as a Report Publication Announcement (RPA). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (PSI). The document's short length (2088 chars) and focus on announcing *when* reports will be published strongly supports the RPA classification.
2023-01-03 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "Pherecydes Pharma annonce son calendrier financier 2023" (Pherecydes Pharma announces its 2023 financial calendar). It explicitly lists future dates for key corporate events such as the release of annual results, the Annual General Meeting (AGM), and interim results. This type of announcement, which communicates the schedule for future report publications and meetings, fits the definition of a Report Publication Announcement (RPA). The document itself is short (2321 characters) and serves to announce when other reports will be released, aligning with Rule #2 (MENU VS MEAL rule).
2023-01-03 French
Informations privilégiées / Autres communiqués
AGM Information Classification · 99% confidence The document title explicitly states "compte rendu de l'Assemblée Générale Mixte du 15 décembre 2022" (Minutes/Report of the Combined General Meeting of December 15, 2022). The text confirms that the shareholders followed the recommendations and details decisions made following the AGM, including management structure changes. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2022-12-15 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document is explicitly titled "Pherecydes Pharma: minutes of the Combined General Meeting of December 15, 2022". It details the resolutions adopted and decisions made during this meeting, including changes in management roles (separation of CEO and Chairman functions). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2022-12-15 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.